Several genetic mutations are identified to play a major role in the progression of this indication. Mutations in EGFR, KRAS, and ALK are mutually exclusive in patients with NSCLC, and the presence of one mutation instead of another can influence response to targeted therapy. Therefore, testing for these mutations and tailoring therapies accordingly is widely accepted as standard practice.